Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SSE:600332

Watchlist Manager
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Logo
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SSE:600332
Watchlist
Price: 29.07 CNY 0.59% Market Closed
Market Cap: 46.8B CNY
Have any thoughts about
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd?
Write Note

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SSE:600332
Long-Term Debt
ÂĄ3.8B
CAGR 3-Years
44%
CAGR 5-Years
46%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Long-Term Debt
ÂĄ104.5m
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Long-Term Debt
ÂĄ158.1m
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
-6%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Long-Term Debt
ÂĄ58.3m
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
19%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Long-Term Debt
ÂĄ195.6m
CAGR 3-Years
43%
CAGR 5-Years
118%
CAGR 10-Years
42%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Long-Term Debt
ÂĄ192.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Glance View

Market Cap
47.3B CNY
Industry
Pharmaceuticals

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. stands as a prominent player in China's healthcare industry, weaving a rich legacy that dates back to its formation in the 20th century. Rooted in the dynamic city of Guangzhou, Baiyunshan reflects a harmonious blend of traditional Chinese medicine (TCM) and modern pharmaceutical innovation. The company's name itself, Baiyunshan—meaning "White Cloud Mountain" in Chinese—symbolizes its foundational connection to the city's cultural heritage and its aspiration to elevate healthcare standards. Baiyunshan's operations are a testament to its multifaceted approach to pharmaceutical production. It delves into the research and development, manufacturing, and distribution of both TCM and Western medicine. This dual approach enables Baiyunshan to cater to a diverse demographic, forging a unique path by merging ancient medical wisdom with cutting-edge scientific advancements. The core of Baiyunshan's business strategy pivots around its expansive product portfolio, which is instrumental in its revenue generation. Pharmaceuticals are at its heart, encompassing a wide range of products from patent medicines to essential drugs that are household names in China. Additionally, the company has successfully branched into the production of over-the-counter (OTC) products, health supplements, and even skincare products, broadening its consumer reach. Meanwhile, Baiyunshan's distribution network—extensive and strategically aligned—stretches across domestic and international markets, ensuring its products are widely accessible. By leveraging strategic partnerships and ongoing innovation, the company continually fortifies its market presence, making Baiyunshan a notable financial performer and a beacon of trust in the healthcare industry.

Intrinsic Value
38.39 CNY
Undervaluation 24%
Intrinsic Value
Price

See Also

What is Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's Long-Term Debt?
Long-Term Debt
3.8B CNY

Based on the financial report for Sep 30, 2024, Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's Long-Term Debt amounts to 3.8B CNY.

What is Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
46%

Over the last year, the Long-Term Debt growth was 1%. The average annual Long-Term Debt growth rates for Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd have been 44% over the past three years , 46% over the past five years .

Back to Top